Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18314830 | 0.92 | FASN (0.34) | CYP2C9ALDH1A1MAPTFASNHTT | |
| SCHEMBL18314924 | 0.86 | CYP2C9 (0.41) | CYP2C9ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL18315073 | 0.86 | KDM1A (0.31) | — | |
| SCHEMBL18314987 | 0.86 | KDM1A (0.31) | — | |
| SCHEMBL18314941 | 0.84 | CYP2C9 (0.33) | CYP2C9ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL18314937 | 0.84 | CYP2C9 (0.39) | CYP2C9ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL18314991 | 0.84 | CYP2C9 (0.39) | CYP2C9ALDH1A1MAPTLMNAMEN1 | |
| SCHEMBL18314947 | 0.83 | CYP2C9 (0.32) | CYP2C9OPRL1ALDH1A1MAPTLMNA | |
| SCHEMBL18310505 | 0.82 | KDM1A (0.36) | CYP2C9OPRL1ALDH1A1MAPTLMNA | |
| SCHEMBL18314894 | 0.82 | CYP2C9 (0.40) | CYP2C9OPRL1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362605-A1 | LIQUID CRYSTAL COMPOUND HAVING 1,1,3,3-TETRAFLUOROALLYLOXY GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | TCOF1, PIEZO1, RCC1 | CYP2C9 1546/4885OPRL1 1258/4885ALDH1A1 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.